生物製剤の開発・製造受託機関市場：タイプ別、製品タイプ別、適応疾患別、サービスタイプ別、エンドユーザー別-2025～2030年の世界予測

生物製剤の開発・製造受託機関市場は、2023年に98億8,000万米ドルと評価され、2024年には105億9,000万米ドルに達すると予測され、CAGR 7.44％で成長し、2030年には163億5,000万米ドルに達すると予測されています。

生物製剤の開発・製造受託機関市場は、細胞培養開発、生産プロセス、分析検査などの不可欠なサービスを提供するバイオ医薬品業界において極めて重要な役割を担っています。生物製剤CDMOの必要性は、社内に能力を持たない製薬会社に専門的なリソースや専門知識を提供する能力から生じる。この市場は、モノクローナル抗体、ワクチン、組換えタンパク質、遺伝子治療に関連する用途を提供し、がん、感染症、慢性疾患など幅広い治療セグメントに対応しています。最終用途プロバイダーは、大手製薬会社から小規模なバイオテクノロジー新興企業まで幅広く、CDMOの能力を活用して医薬品開発を加速し、製品をより早く市場に送り出しています。

主要成長促進要因としては、複雑な疾患の治療におけるその精度と有効性による生物製剤の需要の高まり、バイオプロセスの技術的進歩、運用コストを削減しコアコンピタンスへの集中を強化するためのアウトソーシング傾向の高まりなどが挙げられます。最近のビジネス機会は、CDMOがテーラーメイド治療の急成長セグメントに参入できる個別化医療と、生産に柔軟性とコスト効率を提供するシングルユース技術の採用にあります。企業は、先進的なバイオプロセス技術に投資し、統合開発ソリューションを含むサービス提供を拡大することで、こうした動向を活用することができます。

しかし、厳しい規制要件などの課題は依然として残っており、高いコンプライアンスコストが必要となり、市場投入までの時間を遅らせる可能性があります。また、生物製剤の生産需要の急増に起因する生産能力のボトルネックも市場成長の制約となっており、生産スケジュールに影響を及ぼす可能性があります。技術革新と研究は、連続バイオプロセス技術の開発など、製造のスケーラビリティと効率を高めることによって、これらの限界に対処することに焦点を当てるべきです。さらに、技術開発者との協力関係を改善し、データ分析やAI主導洞察などのデジタル変革に投資することで、事業の成長を促進することができます。この市場の性質は競争的でありながら、コラボレーションの可能性が十分にあるため、競合を維持するためには戦略的パートナーシップと技術革新のバランスが必要です。

市場力学：急速に進化する生物製剤の開発・製造受託機関市場の主要市場洞察を公開

生物製剤の開発・製造受託機関市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 標的治療のための細胞・遺伝子治療に対する需要の高まり
  • 上流と下流処理におけるシングルユース技術の採用拡大
  • 新規バイオ治療開発への注目の高まり
• 市場抑制要因
  • 生物製剤の製造に伴う製品の品質と高コストに関する懸念
• 市場機会
  • バイオプロセス技術の進歩による効率的な大量生産の実現
  • 研究・技術革新への投資拡大と生物製剤の臨床検査数の増加
• 市場課題
  • CDMO組織に対する政府の厳しい法規制

ポーターの5つの力：生物製剤の開発・製造受託機関市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：生物製剤の開発・製造受託機関市場における外部からの影響の把握

外部マクロ環境要因は、生物製剤の開発・製造受託機関市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：生物製剤の開発・製造受託機関市場における競合情勢の把握

生物製剤の開発・製造受託機関市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス生物製剤の開発・製造受託機関市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、生物製剤の開発・製造受託機関市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：生物製剤の開発・製造受託機関市場における成功への道筋を描く

生物製剤の開発・製造受託機関市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 標的治療のための細胞・遺伝子治療の需要増加
    • 上流と下流処理における使い捨て技術の採用の増加
    • 新たなバイオ医薬品の開発への注目が高まる
  • 抑制要因
    • バイオ医薬品製造に伴う製品品質と高コストに関する懸念
  • 機会
    • バイオプロセス技術の進歩により、効率的な大規模生産が可能になった
    • 研究とイノベーションへの投資の増加と生物製剤の臨床検査数の増加
  • 課題
    • CDMO組織に対する厳格な政府法規制
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 生物製剤の開発・製造受託機関市場：タイプ別

• イントロダクション
• 哺乳類
• 非哺乳類

第7章 生物製剤の開発・製造受託機関市場：製品タイプ別

• イントロダクション
• 生物製剤
  • アンチセンスと分子療法
  • モノクローナル
  • 組み換えタンパク質
  • ワクチン
• バイオシミラー

第8章 生物製剤の開発・製造受託機関市場：適応疾患別

• イントロダクション
• 心血管疾患
• 血液疾患
• 免疫疾患
• 腫瘍学

第9章 生物製剤の開発・製造受託機関市場：サービスタイプ別

• イントロダクション
• 細胞株の開発
  • 哺乳類
  • 微生物
• プロセス開発
  • 下流
    • 不純物、分離、識別
    • 医薬品分析
    • 物理化学的特性評価
  • 上流
    • 哺乳類
    • 微生物

第10章 生物製剤の開発・製造受託機関市場：エンドユーザー別

• イントロダクション
• バイオ医薬品企業
• 研究所

第11章 南北アメリカの生物製剤の開発・製造受託機関市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋の生物製剤の開発・製造受託機関市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの生物製剤の開発・製造受託機関市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • Samsung Biologics、バイオシミラーCDMO能力を増強
  • Catalentがバイオロジクスサービスプラットフォームを拡大
  • Asahi Kasei Groupの米国バイオ医薬品CDMOであるBionova Scientificが製造能力を拡大
• 戦略分析と提言

企業一覧

• AbbVie, Inc.
• Abzena Ltd.
• Aenova Holding GmbH
• AGC Biologics GmbH
• Avid Bioservices, Inc.
• Binex Co. Limited
• Boehringer Ingelheim International GmbH
• Cambrex Corporation
• Catalent, Inc.
• Emergent BioSolutions, Inc.
• Fujifilm Holdings Corporation
• Icon PLC
• JSR Life Sciences, LLC
• Lonza Group AG
• Parexel International Corporation
• ProBioGen AG
• Recipharm AB
• Rentschler Biopharma SE
• Samsung Biologics
• Takeda Pharmaceutical Company Limited
• Thermo Fisher Scientific, Inc.
• Toyobo Co., Ltd.
• WuXi Biologics Inc.

LIST OF FIGURES

• FIGURE 1. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET RESEARCH PROCESS
• FIGURE 2. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET DYNAMICS
• TABLE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NON-MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ANTISENSE & MOLECULAR THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MONOCLONAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY IMPURITY, ISOLATION, & IDENTIFICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHYSICOCHEMICAL CHARACTERIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 53. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 58. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 59. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 61. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 62. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 65. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 66. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 67. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 68. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 69. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 70. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 71. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 72. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 75. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 76. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 77. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 78. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 79. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 80. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 81. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 82. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 85. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 86. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 88. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 89. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 90. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 91. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 92. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 95. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 96. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 98. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 99. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 100. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 101. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 102. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 104. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 106. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 107. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 108. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 109. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 110. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 111. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 112. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 113. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 115. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 117. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 118. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 119. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 120. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 121. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 122. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 123. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 124. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 127. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 128. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 129. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 130. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 131. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 132. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 133. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 134. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 137. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 138. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 139. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 140. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 141. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 142. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 143. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 144. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 147. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 148. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 149. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 150. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 151. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 152. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 153. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 154. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 155. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 156. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 157. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 158. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 159. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 160. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 161. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 162. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 163. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 164. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 165. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 166. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 167. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 168. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 169. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 170. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 171. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 172. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 173. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 174. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 175. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 176. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 177. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 178. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 179. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 180. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 181. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 182. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 183. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 184. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 185. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 186. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 187. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 188. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 189. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 190. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 191. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 192. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 193. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 194. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 195. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 196. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 197. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 198. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 199. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 205. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 206. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 207. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 208. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 209. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 210. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 211. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 212. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 213. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 214. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 215. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 216. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 217. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 218. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 219. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 220. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 221. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 222. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 223. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 224. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 225. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 226. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 227. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 228. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 229. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 230. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 231. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 232. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 233. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
• TABLE 234. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 235. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 236. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 237. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
• TABLE 238. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 239. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
• TABLE 240. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 241. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
• TABLE 242. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
• TABLE 243. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UP

The Biologics Contract Development & Manufacturing Organization Market was valued at USD 9.88 billion in 2023, expected to reach USD 10.59 billion in 2024, and is projected to grow at a CAGR of 7.44%, to USD 16.35 billion by 2030.

The Biologics Contract Development and Manufacturing Organization (CDMO) market is pivotal in the biopharmaceutical industry, providing essential services such as cell culture development, production processes, and analytical testing. The necessity of biologics CDMOs arises from their ability to offer specialized resources and expertise to pharmaceutical companies, which may lack in-house capabilities. This market serves applications related to monoclonal antibodies, vaccines, recombinant proteins, and gene therapies, catering to a wide array of therapeutic areas including oncology, infectious diseases, and chronic conditions. End-use providers range from large pharmaceutical firms to small biotech startups, leveraging CDMO capabilities to accelerate drug development and bring products to market faster.

Key growth drivers include the escalating demand for biologics due to their precision and efficacy in treating complex diseases, technological advancements in bioprocessing, and the increasing trend towards outsourcing to reduce operational costs and enhance focus on core competencies. Recent opportunities lie in personalized medicine, where CDMOs can tap into the burgeoning field of tailored therapies, and in the adoption of single-use technology, which offers flexibility and cost-effectiveness in production. Companies could capitalize on these trends by investing in advanced bioprocessing technologies and expanding service offerings to include integrated development solutions.

However, challenges persist, such as stringent regulatory requirements, which necessitate high compliance costs and can delay time-to-market. Market growth is also constrained by capacity bottlenecks stemming from the rapid increase in biologics production demand, which can impact production timelines. Innovation and research should focus on addressing these limitations by enhancing manufacturing scalability and efficiency, such as through the development of continuous bioprocessing technologies. Additionally, improving collaborations with technology developers and investing in digital transformations like data analytics and AI-driven insights can foster business growth. The nature of this market is competitive yet ripe with collaboration potential, necessitating a balance between strategic partnership and technological innovation to maintain a competitive edge.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biologics Contract Development & Manufacturing Organization Market

The Biologics Contract Development & Manufacturing Organization Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising demand for cell and gene therapies for targeted treatment
  • Growing adoption of single-use technologies in upstream and downstream processing
  • Increasing focus on developing novel biotherapeutics
• Market Restraints
  • Concern regarding product quality and high costs associated with biologics products manufacturing
• Market Opportunities
  • Advancement in bioprocessing technologies enabled efficient large-scale production
  • Growing investment in research and innovation and rising numbers of clinical trials for biologics
• Market Challenges
  • Strict governmental laws and regulations for CDMO organizations

Porter's Five Forces: A Strategic Tool for Navigating the Biologics Contract Development & Manufacturing Organization Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biologics Contract Development & Manufacturing Organization Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biologics Contract Development & Manufacturing Organization Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biologics Contract Development & Manufacturing Organization Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biologics Contract Development & Manufacturing Organization Market

A detailed market share analysis in the Biologics Contract Development & Manufacturing Organization Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biologics Contract Development & Manufacturing Organization Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biologics Contract Development & Manufacturing Organization Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biologics Contract Development & Manufacturing Organization Market

A strategic analysis of the Biologics Contract Development & Manufacturing Organization Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biologics Contract Development & Manufacturing Organization Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Abzena Ltd., Aenova Holding GmbH, AGC Biologics GmbH, Avid Bioservices, Inc., Binex Co. Limited, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Emergent BioSolutions, Inc., Fujifilm Holdings Corporation, Icon PLC, JSR Life Sciences, LLC, Lonza Group AG, Parexel International Corporation, ProBioGen AG, Recipharm AB, Rentschler Biopharma SE, Samsung Biologics, Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Inc., Toyobo Co., Ltd., and WuXi Biologics Inc..

Market Segmentation & Coverage

This research report categorizes the Biologics Contract Development & Manufacturing Organization Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Mammalian and Non-mammalian.
• Based on Product Type, market is studied across Biologics and Biosimilars. The Biologics is further studied across Antisense & Molecular Therapy, Monoclonal, Recombinant Proteins, and Vaccines.
• Based on Disease Indication, market is studied across Cardiovascular Disorders, Hematological Disorders, Immunological Disorders, and Oncology.
• Based on Service Type, market is studied across Cell Line Development and Process Development. The Cell Line Development is further studied across Mammalian and Microbial. The Process Development is further studied across Downstream and Upstream. The Downstream is further studied across Impurity, Isolation, & Identification, Pharmaceutical Analysis, and Physicochemical Characterization. The Upstream is further studied across Mammalian and Microbial.
• Based on End-User, market is studied across Biopharmaceutical Companies and Research Laboratories.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising demand for cell and gene therapies for targeted treatment
    • 5.1.1.2. Growing adoption of single-use technologies in upstream and downstream processing
    • 5.1.1.3. Increasing focus on developing novel biotherapeutics
  • 5.1.2. Restraints
    • 5.1.2.1. Concern regarding product quality and high costs associated with biologics products manufacturing
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancement in bioprocessing technologies enabled efficient large-scale production
    • 5.1.3.2. Growing investment in research and innovation and rising numbers of clinical trials for biologics
  • 5.1.4. Challenges
    • 5.1.4.1. Strict governmental laws and regulations for CDMO organizations
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Biologics Contract Development & Manufacturing Organization Market, by Type

• 6.1. Introduction
• 6.2. Mammalian
• 6.3. Non-mammalian

7. Biologics Contract Development & Manufacturing Organization Market, by Product Type

• 7.1. Introduction
• 7.2. Biologics
  • 7.2.1. Antisense & Molecular Therapy
  • 7.2.2. Monoclonal
  • 7.2.3. Recombinant Proteins
  • 7.2.4. Vaccines
• 7.3. Biosimilars

8. Biologics Contract Development & Manufacturing Organization Market, by Disease Indication

• 8.1. Introduction
• 8.2. Cardiovascular Disorders
• 8.3. Hematological Disorders
• 8.4. Immunological Disorders
• 8.5. Oncology

9. Biologics Contract Development & Manufacturing Organization Market, by Service Type

• 9.1. Introduction
• 9.2. Cell Line Development
  • 9.2.1. Mammalian
  • 9.2.2. Microbial
• 9.3. Process Development
  • 9.3.1. Downstream
    • 9.3.1.1. Impurity, Isolation, & Identification
    • 9.3.1.2. Pharmaceutical Analysis
    • 9.3.1.3. Physicochemical Characterization
  • 9.3.2. Upstream
    • 9.3.2.1. Mammalian
    • 9.3.2.2. Microbial

10. Biologics Contract Development & Manufacturing Organization Market, by End-User

• 10.1. Introduction
• 10.2. Biopharmaceutical Companies
• 10.3. Research Laboratories

11. Americas Biologics Contract Development & Manufacturing Organization Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Biologics Contract Development & Manufacturing Organization Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Biologics Contract Development & Manufacturing Organization Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Biosimilar CDMO Capacity Increased in Samsung Biologics
  • 14.3.2. Catalent expands its biologics services platform
  • 14.3.3. Bionova Scientific, U.S. biologics CDMO of the Asahi Kasei Group, expands manufacturing capacity
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie, Inc.
• 2. Abzena Ltd.
• 3. Aenova Holding GmbH
• 4. AGC Biologics GmbH
• 5. Avid Bioservices, Inc.
• 6. Binex Co. Limited
• 7. Boehringer Ingelheim International GmbH
• 8. Cambrex Corporation
• 9. Catalent, Inc.
• 10. Emergent BioSolutions, Inc.
• 11. Fujifilm Holdings Corporation
• 12. Icon PLC
• 13. JSR Life Sciences, LLC
• 14. Lonza Group AG
• 15. Parexel International Corporation
• 16. ProBioGen AG
• 17. Recipharm AB
• 18. Rentschler Biopharma SE
• 19. Samsung Biologics
• 20. Takeda Pharmaceutical Company Limited
• 21. Thermo Fisher Scientific, Inc.
• 22. Toyobo Co., Ltd.
• 23. WuXi Biologics Inc.